Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients
Purpose Germline promoter hypermethylation of BRCA1 and BRCA2 genes is an alternative event of gene silencing that has not been widely investigated in hereditary breast and ovarian cancer (HBOC) syndrome. Methods We analyzed germline BRCA promoter hypermethylation in HBOC patients with and without B...
Gespeichert in:
Veröffentlicht in: | Clinical & translational oncology 2018-09, Vol.20 (9), p.1226-1231 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose
Germline promoter hypermethylation of
BRCA1
and
BRCA2
genes is an alternative event of gene silencing that has not been widely investigated in hereditary breast and ovarian cancer (HBOC) syndrome.
Methods
We analyzed germline
BRCA
promoter hypermethylation in HBOC patients with and without
BRCA
mutations and control subjects, using a recently developed BRCA methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.
Results
Neither the patients tested nor the control subjects showed germline hypermethylation of the
BRCA1
and
BRCA2
promoter regions analyzed.
Conclusions
Despite the results achieved at somatic levels by other researchers, these were not confirmed in our study at the germline level. Our results show the need to establish more predictive CpG sites in the
BRCA
promoter regions to optimize the MS-MLPA assay for the detection of germline hypermethylation as an effective pre-screening tool for whole-BRCA genetic analysis in HBOC, because we can not rule out the existence of germline promoter hypermethylation in
BRCA
. |
---|---|
ISSN: | 1699-048X 1699-3055 |
DOI: | 10.1007/s12094-018-1837-0 |